FindTrial
Sign In

effects of inrtavenous magnesium sulphate on bupivacaine in women with preeclampsia

effects of inrtavenous magnesium sulphate on intrathecal bupivacaine in women with preeclampsia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15006856
Enrollment
Unknown
Registered
2015-07-27
Start date
2015-07-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bupivacaine

Interventions

GROUP MG:nrtavenous magnesium sulphate
Control:0.9%NS

Sponsors

Jiaxing Maternity and Child Health Care Hospital,
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: women with preeclampsia

Exclusion criteria

Exclusion criteria: Lumbar hemp contraindications

Design outcomes

Primary

MeasureTime frame
effect;—

Countries

China

Contacts

Public ContactZhang Wangping
zhang650679@163.com+86 13757370679

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026